Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study

May 24, 2022

Yesterday California-based Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was in the news after the biotech company made a major announcement with regard to one of its products. Trading Data On Monday, ARMP stock ended flat at $4.25 with more than 472 million shares, compared to its average volume of 9.9K shares. The stock moved within a range of $4.1700 – 4.2500 after opening trading at $4.17. Key Details The company announced that it…